Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Subcutaneous Durvalumab in Solid Tumours
NCT07391670Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Primary completion
- Aug 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 5
01
Overview
Phase 1, open-label trial of durvalumab in solid tumor, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC) and 1 more (3 arms), sponsored by AstraZeneca. Primary endpoints: Area under the concentration-time curve at 17 months and Observed lowest concentration before the next dose is administered at 17 months. Started Mar 2026; status: recruiting.
02
Drugs
durvalumab
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07391670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07391670.